Print

Study of a New InvestigationaI Inhibitor to Treat People with Advanced Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/300/study-of-a-new-investigationai-inhibitor-to-treat-people-with-advanced-solid-tumors

Clinicaltrials.gov identifier:
NCT05932862 (https://clinicaltrials.gov/show/NCT05932862)

Treatment
Treatment study for people with advanced solid tumors

Study Contact Information:

Please contact Exelixis Clinical Trials by phone 1-888-393-5494 or email [email protected]


About the Study

The study will test if an investigational treatment, XL309, is safe and works when used alone or in combination with a PARP inhibitor to treat people with some advanced solid tumors. The study is looking to enroll adults with certain types of cancer, including those with:

XL309 is an inhibitor that blocks an enzyme called USP1. Blocking USP1 in cancer cells may prevent tumors from repairing their damaged DNA, causing the cancer cells to die.

Some people in the study will be treated with XL309 in combination with olaparib. Olaparib is an inhibitor that blocks an enzyme called PARP. Olaparib is approved to treat certain cancers, including some forms of breast cancer, ovarian cancer, pancreatic cancer and prostate cancer.

The use of XL309, alone or in combination with olaparib, is being investigated in this clinical trial and has not been approved by the FDA. Safety and efficacy have not been established and are being studied as part of this trial.

What the Study Involves

This is a phase 1, open-label study, which means if you take part in the study, you and your doctor will know which drug(s) are being given. The study will be run in two different parts:

If you are eligible and decide to take part in the XL309 study:

The time between visits will depend on which part of the study you join.

Talk to your doctor to learn more about this study and if it may be an option for you.

Study Locations

Texas

Austin
Next Oncology

Houston
MD Anderson Cancer Center

San Antonio
Next Oncology

 

 

 


This Study is Open To:

People may be eligible who: 

Note: If you had treatment with a PARP inhibitor before, you may be eligible for the study. Talk to the study doctor about how your body tolerated prior PARP inhibitor therapy to see if you are eligible for this study treatment.

There are other requirements to participate in this study. The study doctor will help determine if this study is right for you.

This Study is Not Open To:

People may not be eligible who:

There are other requirements to participate in this study. The study doctor will help determine if this study is right for you.


About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.